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ABSTRACT
The hepatic endoplasmic reticulum (ER)–anchored monotopic
proteins, cytochromes P450 (P450s), are enzymes that metab-
olize endobiotics (physiologically active steroids and fatty acids),
as well as xenobiotics including therapeutic/chemotherapeutic
drugs, nutrients, carcinogens, and toxins. Alterations of hepatic
P450 content through synthesis, inactivation, or proteolytic
turnover influence their metabolic function. P450 proteolytic
turnover occurs via ER-associated degradation (ERAD) involving
ubiquitin (Ub)-dependent proteasomal degradation (UPD) as
a major pathway. UPD critically involves P450 protein ubiquitina-
tion by E2/E3 Ub-ligase complexes. We have previously identified
the ER-polytopic gp78/AMFR (autocrine motility factor receptor)
as a relevant E3 in CYP3A4, CYP3A23, and CYP2E1 UPD. We
now document that liver-conditional genetic ablation of gp78/
AMFR in male mice disrupts P450 ERAD, resulting in statistically
significant stabilization of Cyp2a5 andCyp2c, in addition to that of
Cyp3a and Cyp2e1. More importantly, we establish that such
stabilization is of the functionally active P450 proteins, leading to
corresponding statistically significant enhancement of their drug-
metabolizing capacities. Our findings, with clinically relevant
therapeutic drugs (nicotine, coumarin, chlorzoxazone, and acet-
aminophen) and the prodrug (tamoxifen) as P450 substrates,
reveal that P450 ERADdisruption could influence therapeutic drug
response and/or toxicity, warranting serious consideration as
a potential source of clinically relevant drug-drug interactions
(DDIs). Because gp78/AMFR is not only an E3 Ub-ligase, but also
a cell-surface prometastatic oncogene that is upregulated in
various malignant cancers, our finding that hepatic gp78/AMFR
knockout can enhance P450-dependent bioactivation of relevant
cancer chemotherapeutic prodrugs is of therapeutic relevance
and noteworthy in prospective drug design and development.
SIGNIFICANCE STATEMENT
The cell-surface and ER transmembrane protein gp78/AMFR,
a receptor for the prometastatic autocrine motility factor (AMF),
as well as an E3 ubiquitin-ligase involved in the ER-associated
degradation (ERAD) of not only the tumor metastatic suppressor
KAI1 but also of hepatic cytochromes P450, is upregulated in
various human cancers, enhancing their invasiveness, meta-
static potential, and poor prognosis. Liver-specific gp78/AMFR
genetic ablation results in functional protein stabilization of
several hepatic P450s and consequently enhanced drug and
prodrug metabolism, a feature that could be therapeutically
exploited in the bioactivation of chemotherapeutic prodrugs
through design and development of novel short-term gp78/
AMFR chemical inhibitors.
Introduction
Luminal and membrane-bound endoplasmic reticulum
(ER) proteins incur proteolytic turnover via ubiquitin
(Ub)-dependent proteasomal degradation (UPD) in a physio-
logic process termed “ER-associated degradation” (ERAD)
(Olzmann et al., 2013; Christianson and Ye, 2014; Preston
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ABBREVIATIONS: ALD, autophagy-lysosomal degradation; ALT, alanine aminotransferase; AMF, autocrine motility factor; AMFR, AMF-receptor;
APAP, acetaminophen; CEC, 3-cyano-7-ethoxycoumarin; cgt, conditional gene trap; CHIP, carboxy-terminus of Hsc70-interacting protein; Cre,
Cre-recombinase; Ct, threshold cycle; DDIs, drug-drug interactions; DEX, dexamethasone; ER, endoplasmic reticulum; ERAD, ER-associated
degradation; flp, floxed; Flpe, flippase; FMO3, flavin-monooxygenase; HPLC-MS, high-performance liquid chromatography–mass spectrometry; IB,
immunoblotting; INH, isoniazid; KO, knockout; 3-MA, 3-methyladenine; MDA, malondialdehyde; MFC, 7-methoxy-4-(trifluoromethyl)-coumarin;
NAPQI, N-acetylparaquinoneimine; NASH, nonalcoholic steatohepatitis; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; P450, cytochrome
P450; PB, phenobarbital; PCR, polymerase chain reaction; shRNAi, short-hairpin RNA interference; Ub, ubiquitin; UPD, Ub-dependent proteasomal
degradation; WT, wild type.
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and Brodsky, 2017; Needham et al., 2019). This vital process is
critical for the protein quality control required to mitigate the
unfolded protein response triggered by ER stress and/or other
cellular stresses, as well as for the normal physiologic
ER-protein turnover (Olzmann et al., 2013; Christianson
and Ye, 2014; Preston and Brodsky, 2017). Accordingly, we
have found that the hepatic monotopic ER–anchored cyto-
chromes P450 (P450s; CYPs) incur ERAD not just upon their
mechanism-based inactivation that structurally damages the
proteins but also in the course of their physiologic turnover
(Correia et al., 1992; Wang et al., 1999; Faouzi et al., 2007).
Human hepatic P450s are responsible for the metabolism and
elimination of approx. 74% of therapeutically relevant drugs
and participate in many drug-drug interactions (DDIs) and
drug-related toxicities (Guengerich, 2015; Correia, 2018). The
ERAD of human and rat hepatic P450s CYP3A4, CYP3A23,
and CYP2E1 involves an initial Ser/Thr-phosphorylation by
protein kinases A and C (Eliasson et al., 1992, 1994; Wang
et al., 2001, 2009, 2011, 2012, 2015), their ubiquitination via
Ub-activation enzymes E1 and E2/E3-Ub conjugation com-
plexes (Morishima et al., 2005; Pabarcus et al., 2009; Wang
et al., 2009, 2011, 2012; Kim et al., 2010), their extraction from
the ER by p97/Ufd1/Npl4-AAA ATPase complex, and sub-
sequent delivery to the 26S proteasome (Liao et al., 2006;
Faouzi et al., 2007; Acharya et al., 2011).
In vitro functional reconstitution studies (Morishima et al.,
2005; Pabarcus et al., 2009; Kim et al., 2010) of E1/E2/E3-
mediated CYP3A4 and CYP2E1 ubiquitination have led to the
identification of UbcH5a/Hsp70/CHIP and UBC7/gp78/AMFR
complexes as two relevant E2/E3 systems in CYP3A4 and
CYP2E1 ubiquitination: CHIP (carboxy-terminus of Hsc70-
interacting protein), a cytoplasmic Hsc70-cochaperone,
functions with its cognate UbcH5a E2 and Hsc70/Hsp70 in
substrate ubiquitination (Ballinger at al., 1999; Connell
et al., 2001; Jiang et al., 2001; Murata et al., 2001).
gp78/AMFR (autocrine motility factor receptor) is a polytopic,
transmembrane cell surface protein (Nabi et al., 1990), as well
as anER-integral proteinwith a cytoplasmic domain containing
a RING-finger and other subdomains critical to its recruit-
ment of its cognate E2 (UBC7 or Ube2G2) and catalytic E3-
ligase–mediated ubiquitination role (Fang et al., 2001; Zhong
et al., 2004; Chen et al., 2006, 2012; Joshi et al., 2017).
Our lentiviral short-hairpin RNA interference (shRNAi)
analyses targeted individually against CHIP and gp78 veri-
fied their roles in CYP3A and CYP2E1 ubiquitination and
ERAD in cultured rat hepatocytes (Kim et al., 2010). Thus,
upon CHIP knockdown, CYP3A was stabilized largely as the
parent (55-kDa) species along with a minor CYP3A fraction
consisting of its high molecular mass ubiquitinated species.
Similar stabilization of CYP3A parent species was also found
upon gp78 knockdown, albeit with an appreciable fraction as
its ubiquitinated species. Nevertheless, upon either E3 knock-
down of CHIP or gp78, the functionally active CYP3A fraction,
albeit proportional to the relative amount of the stabilized
parent protein, was statistically significantly greater than
that in the corresponding control (nontargeting) shRNA-
treated hepatocytes (Kim et al., 2010). Furthermore, in vitro
reconstitution studies of each CYP3A4 E2/E3-ubiquitination
system, individually and in combination, revealed that al-
though each system by itself was capable of CYP3A4 ubiquiti-
nation, this was both greatly accelerated and potentiated
when both systems were present simultaneously (Wang et al.,
2015). Thus, the sequential introduction of each E2/E3 in the
reconstituted CYP3A4-ubiquitination system revealed that
UbcH5a/CHIP most probably serves as the E3, whereas
UBC7/gp78 serves as the E4 involved in the elongation of
CYP3A4 polyUb chains (Wang et al., 2015).
Consistent with shRNAi findings, Cyp2e1 was also stabilized
in a functionally active form upon mouse CHIP knockout (KO)
(Kim et al., 2016a). This functional Cyp2e1 stabilization was
associated with increased hepatic lipid peroxidation, microvesic-
ular steatosis, and eventually, upon aging, with macrovesicular
steatosis and liver injury characteristic of the nonalcoholic
steatohepatitis (NASH) syndrome (Kim et al., 2016a).
To determine whether genetic ablation of gp78, the other
E3 Ub-ligase identified as relevant to hepatic CYP3A4 and
CYP2E1 ERAD, had similar consequences, we generated
a mouse liver-conditional gp78-KO (gp782/2) model. This
gp782/2 model enabled us not only to examine the role of
gp78-mediated ubiquitination in the ERAD and consequent
physiologic function of Cyps 3a and Cyp2e1 but also to identify
additional hepatic P450s as potential gp78-ubiquitination
targets and to determine their therapeutic/toxicological con-
sequences. Our findings are described herein.
Materials and Methods
Generation of a Liver-Conditional gp78-KO Mouse. Cryopre-
served mouse embryos carrying a conditional amfrtma1(Komp)Wtsi gene-
trap knockout-first allele inserted into amfr intron 2 with loxP sites
flanking exon 3 of amfr were generated as described (Skarnes et al.,
2011; Bradley et al., 2012), resuscitated, cultured, and transplanted
into oviducts of pseudopregnant females of C57BL/6J-Tyrc-Brd;
C57BL/6N background, at the UC Davis Knockout Mouse Project
Facility. Upon weaning, the heterozygous conditional gene-trap (cgt)
genotype of the pups was confirmed by polymerase chain reaction
(PCR) analyses. Mice aged 6 weeks were shipped to UCSF LARC
Transgenic Barrier Facility, where the loxP-flanking sequence was
deleted through mating of 8-week-old heterozygous females with
transgenic male mice (C57BL/6J-background) carrying Flpe (flippase)
recombinase driven by the b-actin promoter (Flpe-deleter; b-actin-
Flp), and of corresponding heterozygous males with female Flpe-mice.
After several intercrosses, homozygous gp78-floxed (flp/flp) mice were
obtained. To generate liver-specific gp78 KOs, flp/flp mice were
crossbred with Alb-Cre-recombinase (Cre)/Alb-Cre (B6.Cg-Tg(Alb-
cre)21Mgn/J) mice (Postic and Magnuson, 2000). The resulting flp/1,
Alb-Cre/1 mice were then crossed again with flp/flp mice to generate
flp/flp, Alb-Cre/1mice as liver-specific gp78KOs. The primers (Tables 1
and 2) used for the tail-clip genotyping were located as indicated by the
arrows (Fig. 1A). Mice were fed a standard chow diet and maintained
under 12-hour light/dark cycle. All animal experimental protocols were
approved by the UCSF/Institutional Animal Care and Use Committee.
Primary Mouse Hepatocyte Cultures. Male mice, 8 to 9 weeks
of age, were used throughout because in our preliminary studies,
specific hepatic Cyp3a isoforms exhibited sex-dependent differences in
content upon liver-conditional gp78-ablation (S.M. Kim and M.A.
Correia, unpublished findings). Hepatocyte isolation from male
gp781/1:Alb-Cre [wild-type (WT); gp781/1] and gp782/2:Alb-Cre
(KO; gp782/2) mice was carried out by in situ liver perfusion with
collagenase and purification by Percoll-gradient centrifugation by the
UCSF Liver Center Cell Biology Core as described previously (Han
et al., 2005). In a few studies, freshly isolated primary hepatocytes
were used for monitoring the basal, hepatic constitutive P450 isoform
content (see below). Alternatively, freshly isolated hepatocytes were
cultured (3.0  106 cells/plate) on 60-mm Permanox plates (Thermo
Fisher Scientific, Waltham, MA) coated with Type I collagen, and
incubated in William’s E Medium containing 2 mM L-glutamine,
642 Kwon et al.
 at A
SPET Journals on February 18, 2020
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
penicillin-streptomycin, insulin-transferrin-selenium, 0.1% bovine se-
rum albumin fraction V, and 0.1 mM dexamethasone (DEX). Cells were
allowed to attach to the plates for 6 hours, before Matrigel (Matrigel
Matrix; Corning Inc., New York) was overlaid and cell cultures allowed
to stabilize for 2 days, during which the initial basal P450 content was
almost completely lost. To restore functional P450 cellular content, after
a 2-day stabilization, cultured primary hepatocytes were treated for
3 days with the following P450-inducers: b-naphthoflavone (b-NF;
25 mM; Cyp1a2), phenobarbital (PB; 1 mM; Cyps 2a, 2b and 2c), DEX
(10 mM; Cyps 3a), and isoniazid (INH; 1 mM, Cyp2e1).
Determination of Relative P450 Protein Content in Freshly
Isolated or Cultured gp78-KO and WT Mouse Hepatocytes. In
certain studies, freshly isolated hepatocytes were lysed in cell lysis
buffer (Cell Signaling Technology, Inc., Danvers, MA) and directly
used for immunoblotting (IB) analyses of constitutive P450s. In
others, upon inducer treatment, cultured cells were harvested in the
same cell lysis buffer. In either case, cell lysates were cleared by
centrifugation (14,000g, 10 minutes, 4°C), and P450 proteins in the
supernatant were subjected to Western IB analyses. Commercial
primary antibodies were used for detecting Cyp1a2 (mouse mono-
clonal, cat. no. 14719; Cell Signaling Technology, Inc.), Cyp2a (rabbit
polyclonal, cat. no. ab3570; Abcam, Cambridge, UK), and Cyp2d
(rabbit polyclonal, cat. no. GTX56286; Genetex, Inc. Irvine, CA).
Purified antibodies from rabbit (Cyp2b, Cyp2c, and Cyp2e1) and from
goat (Cyps 3a) sera were also used as previously described (Kim et al.,
2016a,b). Immunoblots were densitometrically quantified through
NIH Image J software analyses.
Relative P450 mRNA Expression in Cultured WT and
gp78-KO Mouse Hepatocytes. bNF- and INH-pretreated cultured
WT and gp78-KO hepatocytes were used for Cyp1a2 and Cyp2e1
mRNA level determination, respectively; PB-pretreated hepatocytes
were used for monitoring Cyp2a5, 2b10, 2c29, 2c39, and 2d10
mRNA levels, whereas DEX-pretreated hepatocytes were used for
monitoring Cyp3a11 and Cyp3a13 mRNA levels. On day 4, total
RNA was extracted from the cultured hepatocytes with RNeasy
mini-kit (Qiagen, Hilden, Germany), and cDNA was synthesized
using SuperScript IV VILOMaster Mix (Thermo Fisher Scientific).
Hepatic P450 mRNA expression was determined by quantitative
real-time (qRT)-PCR analyses, using SYBR Green PCRMaster Mix
(Applied Biosystems, Foster City, CA), and monitored by Agilent
Mx3005P System (Agilent Technologies, Santa Clara, CA).
Relative gene expression level of each P450 was determined by
normalizing its threshold cycle (Ct) to that of GAPDH Ct. Primers
used are listed (Table 3).
Cyp2a Ubiquitination and Degradation Analyses. Cultured
PB-pretreated hepatocytes were subjected to cycloheximide-chase
analyses by treatment on day 4 at 0 hour with cycloheximide 50 mg/ml
with or without the proteasome inhibitor bortezomib (10 mM), or
the autophagy-lysosomal degradation (ALD) inhibitors, 3-methyladenine
(3-MA; 5mM/NH4Cl; 50mM) for 0, 8, and 24 hours. Cells were harvested
and the lysates were used for Cyp2a IB analyses.
Cyp2a5 ubiquitination analyses were conducted following P450
immunoprecipitation from the lysates (200 mg protein) of hepatocytes
treated with or without bortezomib (10 mM) for 8 hours. Immunopre-
cipitates were incubated with Cyp2a antibody at 4°C overnight. The
antibody-antigen complexes were captured by incubation with Dyna-
beads protein G (Thermo Fisher Scientific) at room temperature for
2 hours and then eluted by heating at 95°C for 10 minutes in 2
volume of SDS-PAGE loading buffer. The ubiquitinated P450s were
detected by Western IB analyses with a mouse monoclonal Ub-antibody
(cat. no. ab7254; Abcam plc), as described previously (Wang et al., 1999,
2015; Kim et al., 2010).
Fluorescence-Based Screening of P450 Functional Markers
in Cultured Mouse Hepatocytes. P450 functional activities in
cultured primary hepatocytes were determined by the method of
Donato et al. (2004), as previously described (Kim et al., 2010). On day
4 after P450-inducer pretreatment, hepatocytes were incubated with
P450 substrates, 3-cyano-7-ethoxycoumarin (CEC, 30 mM; Cyp1a2;
cat. no. 451014.; Corning Inc.), coumarin (CM, 50mM;Cyp2a5; cat. no.,
C4261; Sigma-Aldrich Corp., St. Louis, MO), 7-ethoxy-4-(trifluoro-
methyl)-coumarin (EFC, 30 mM; Cyp2b; cat. no. T2803; Sigma-Aldrich
Corp.), dibenzylfluorescein (DBF, 10 mM; Cyp2c; cat. no. 451740;
Corning Inc.), 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-
4-methylcoumarin (AMMC, 100 mM; Cyp2d; cat. no. 451700; Corning
Inc.), 7-methoxy-4-(trifluoromethyl)-coumarin (MFC, 10 mM; Cyp2e1;
cat. no. 451740; Corning Inc.), or 7-benzyloxy-4-trifluoromethylcou-
marin (BFC, 100 mM; Cyp3a; cat. no. B5057; Sigma-Aldrich Corp.) at
time 0 hour. The media containing CEC metabolite 3-cyano-7-
hydroxycoumarin (CHC; cat. no. 451015; Corning Inc.), CMmetabolite
7-hydroxycoumarin (7-HC; cat. no. H24003; Sigma-Aldrich Corp.),
BFC, EFC, and MFC metabolite 7-hydroxy-4-trifluoromethylcou-
marin (HFC; cat. no. 451731; Corning Inc.), or DBF metabolite
fluorescein (cat. no. 46955; Sigma-Aldrich Corp.), along with their
glucuronide and sulfate conjugates formed during the assay were
collected at defined time points. The AMMC metabolite AMHC was
commercially unavailable, and thus 3-[2-(diethylamino)ethyl]-7-hy-
droxy-4-methylcoumarin (AHMC; cat. no. 188611; Sigma-Aldrich
Corp.) was used instead as previously described for the fluorescence
quantification (Donato et al., 2004). The conjugates were hydrolyzed
by incubation of the media with glucuronidase/arylsulfatase (150
Fishman units/ml and 1200 Roy units/ml, respectively) for 2 hours at
37°C. The medium concentrations of CEC, 7-HC, HFC, fluorescein,
and AHMC were fluorometrically monitored at the wavelength
[excitation (nanometer)/emission (nanometer)] of 408/455, 355/460,
TABLE 1
Summary of the primer sequences used for genotyping
Primer Name Nucleotide Sequence (59-39)
1: CSD‐ LoxP‐common forward GAGATGGCGCAACGCAATTAAT
2: Gene‐specific reverse (SR1) CAGAGATTCTACCTCCTGAGTGCTGG
3: WT‐F GGATCTGAAATTCACTGAGCAGTGC
4: WT‐TTR TGTACATGTTCCTTCATGTGAGGAAG
5: CSD-LoxF GAGATGGCGCAACGCAATTAATG
6: CSD-Amfr-R ACCTCCTGAGTGCTGGGATTAAAGG
flpF CACCTAAGGTCCTGGTTCGTCA
flpR CCCAGATGCTTTCACCCTCACT
creF CATTTGGGCCAGCTAAACAT
creR TAAGCAATCCCCAGAAATGC
cre, Cre-recombinase; F, forward; R, reverse.
TABLE 2
Summary of the PCR product (amplicon) size for each primer pair and the
corresponding genotype represented
Primer Pairs Band Size (bp) Genotype
112 337 Cgt (conditional gene-trap cassette)
314 200 Wild type (WT)
flpF1flpR 435 With flpe recombinase (flpe)
516 327 Floxed (fl)
creF1creR 233 With Cre recombinase
cre, Cre-recombinase; F, forward; R, reverse.
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410/510, 485/538, and 390/460, respectively, using the commercially
purchased metabolites as authentic standards.
Nicotine Metabolism in Cultured Mouse Hepatocytes. WT
and gp78-KO hepatocytes were PB-pretreated as described above. On
day 4, (–)-nicotine (500mM)was added at time 0 hour and the cells and
media were collected at 2, 4, 8, and 24 hours, and incubated with
glucuronidase/arylsulfatase for 2 hours at 37°C. The reaction was
stopped by the addition of ice-cold 30% perchloric acid, and the
precipitated proteins were sedimented by centrifugation (15,000g,
10 minutes, 4°C). Nicotine metabolites (cotinine and trans-39-hydrox-
ycotinine, nornicotine, norcotinine, nicotine-N-oxide, and cotinine-N-
oxide) were extracted from the supernatant and quantified by liquid
chromatography–tandem mass spectrometry (LC-MS/MS) analyses
as described for cotinine and trans-39-hydroxycotinine (Jacob et al.,
2011), with minor modifications for the additional analytes (Benowitz
et al., 2010,Wang et al., 2018a). Themetabolites were found largely in
the media, with relatively much smaller levels detected in the cell
lysates.
Tamoxifen Metabolism in Cultured Mouse Hepatocytes.
Cyp3a was induced by DEX-pretreatment of primary hepatocytes as
described above. On day 4, cultured hepatocytes were treated with
tamoxifen (40 mM) for 2, 4, and 8 hours. The concentrations of tamoxifen
and its metabolites, 4-hydroxytamoxifen,N-desmethyltamoxifen, and
endoxifen, in the media were determined using a high-performance
liquid chromatography–mass spectrometric (HPLC-MS) assay
(Dahmane et al., 2010; Binkhorst et al., 2011). Toremifen was
employed as an internal standard, and spiked into the media at
1 mM. The medium was incubated with glucuronidase/arylsulfatase
for 2 hours at 37°C and the reactions terminated by the addition of 2
volume of ice-cold acetonitrile containing 0.1% formic acid. Precipi-
tated proteins were removed by sedimentation at 10,000g for
10 minutes at 4°C, and an aliquot (300 ml) of the supernatant was
mixedwith 50mMglycine buffer (pH 11.5; 700ml). An aliquot (50ml) of
this mixture was injected into the HPLC system (Waters Separation
Module 2695; Waters Corporation, Milford, MA), equipped with
a C18 reversed-phase column (100  2.1 mm, 3 mm, Hypersil Gold
Fig. 1. Strategy for generating the liver-conditional gp78/AMFR-KOmousemodel and corresponding validation. (A) Conditional gene trap (cgt) strategy
to develop gp78-floxed (gp78f) mice and, subsequently, liver-conditional gp78-KO mice (gp782). Arrows indicate the sites of the genotyping primers
employed. (B andC) PCR genotype analyses of genomic DNA isolated via tail-clipping ofmice at various stages of the strategy. SeeMaterials andMethods
for experimental details. The primer pairs for each genotyping product and the corresponding amplicon size are indicated. flpF/flpR primers used to verify
the amplicon obtained upon Flpe recombinase in WT (1/1); cgt/1, heterozygous with the cgt-cassette insert; and cgt/cgt, homozygous with the cgt-
cassette insert. Amplicons verifying WT gp78 (1/1), Alb/Cre, heterozygous gp78-KO (1/2), and Alb-Cre and homozygous gp78-KO (2/2), each Alb-Cre
carrying an Alb-Cre allele upon mating with Alb-Cre/Alb-Cre mice. (D) IB analyses of liver and brain lysates from WT and KO mice with a rabbit anti-
mouse gp78-antibody, verifying the liver-specific gp78 KO.
TABLE 3
Primers used for qRT-PCR analyses of P450 mRNA expression
Gene Sequence 59 → 39
Cyp1a2 ATGATGAGAAGCAGTGGAAAGA CAGGATGGCTAAGAAGAGGAAG
Cyp2a5 CACCCAGATATTGAGGCCAA CCCAGCATAGGAAACACTTCA
Cyp2b10 AGGAGGAAGCCCAATGTTTAG CTCAAACATCTGGCTGGAGAA
Cyp2c29 GTCACAGCTAAAGTCCAGGAAG TCATGCAGCACTGATGACAG
Cyp2c39 GCAGGTCTGCAATAATTTCCC GTTGGATGTGATTTGCCTGTT
Cyp2d10 CTGGCAGAGATAGAGAAGGTAAAG CCCTATGACCGCATCGATTT
Cyp2e1 TCCTCATAGAGATGGAGAAGGAAA GGCCCAATAACCCTGTCAAT
Cyp3a11 GTGAACGTGGATTCCCTCAA CTCGGTGCTTCTGCTTAGAAT
Cyp3a13 TACCCTGCTACAGATGGAGTAT CTGATTCTTCTTGCTGAACCTTTC
gapdh ACCACAGTCCATGCCATCAC CACCACCCTGTTGCTGTAGCC
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aQ; Thermo Fisher Scientific), and maintained at a temperature
of 30°C. An aqueous solution containing 0.1% formic acid was used
as the mobile phase A, and acetonitrile containing 0.1% formic
acid was used as the mobile phase B. Mobile phases A (30%) and
B (70%) were applied isocratically at a flow rate of 0.2 ml/min.
The peaks were detected at 254 nm by Waters dual absorbance
detector 2487 (Waters Corporation). The retention times of endox-
ifen, 4-hydroxytamoxifen, toremifen, N-desmethyltamoxifen,
and tamoxifen were 9.26, 11.16, 22.17, 23.77, and 26.92 minutes,
respectively. The HPLC system was connected to a Waters Micro-
mass ZQ single quadrupole mass analyzer (Waters Micromass
Corporation, Manchester, U.K.), equipped with an electrospray
ionization probe operated in the positive ionization mode. The ion-
spray and cone voltage were 3 kV and 45 V, respectively. The
protonated molecular ion [M1H]1 masses of N-desmethyltamoxifen,
tamoxifen, endoxifen, 4-hydroxytamoxifen, and toremifen were
found to be 358.2, 372.2, 374.2, 388.2, and 406.2 amu, respectively.
ChlorzoxazoneMetabolism in CulturedMouse Hepatocytes.
Cultured primary WT and KO mouse hepatocytes were INH-
pretreated to induce Cyp2e1, as described above. On day 4, at time
0 hour, chlorzoxazone (400 mM) was added to the hepatocytes for
3 hours. The 6-hydroxychlorzoxazone (6-OH CZX) formed by
Cyp2e1 was monitored by HPLC as described (Girre et al., 1994)
with a slight modification. The collected medium was first in-
cubated with glucuronidase/arylsulfatase for 2 hours at 37°C, and
the reaction stopped with 40% perchloric acid. After sedimentation
of the precipitated protein, the supernatant was mixed with 1.5
volume of ethyl acetate by vigorous vortex mixing for 20 minutes.
The upper organic phase was collected and evaporated at 40°C. The
resulting residue was reconstituted with 100 ml of mobile phase,
acetonitrile, and 0.5% acetic acid (30:70, v/v, pH 3), and a 50-ml
aliquot was injected into a Varian Prostar HPLC (Varian Inc., Palo
Alto, CA) system, equipped with a Grace Prosphere 100 C18, 5 mm,
4.6-  150-mm column (Thermo Fisher Scientific) for metabolite
separation at a flow rate of 1.1ml/min. of 6-OH-CZX (retention time
of 7.6 minutes) was detected at 287 nm with a Varian Prostar 335
UV detector (Varian Inc.).
Acetaminophen-Induced Hepatotoxicity. Cultured mouse he-
patocytes pretreated with INH (1 mM) for 3 days were used for the
acetaminophen (APAP) toxicity assay. On day 4, hepatocytes were
incubated with APAP (1 or 5 mM) and the medium was collected at 2,
4, 8, and 24 hours. The medium alanine aminotransferase (ALT)
activity was quantified using the ALT assay kit (MAK052; Sigma-
Aldrich Corp.).
In Vivo APAP-Induced Hepatotoxicity in Liver-Specific
gp78-KO Mice. Male 8 week-old C57BL/6 mice (WT, n 5 5; gp78
KO, n 5 5) were fasted overnight (12 hours). APAP (200 mg/kg, i.p.)
dissolved in 0.9% NaCl solution (10 ml/kg) was injected into the mice
at time 0 hour. Blood was collected from the facial vein at 0, 6, and
12 hours after the injection, and the mice were killed at 12 hours to
collect the liver tissue. Serum was isolated from the whole blood and
ALT levels were monitored as described above. Hepatic malondialde-
hyde (MDA) levels were measured using liver homogenates by the
TBARS assay kit (cat. no. 10009055; Cayman Chemical, Ann Arbor,
MI). Cyp2e1 and Cyp3a protein levels in liver homogenate (5 mg) were
determined byWestern IB analyses using corresponding antibodies as
indicated above. Fresh liver tissues were stored in 10% neutral
buffered formalin, and the tissue sections were stained with hema-
toxylin and eosin. Microscopic histopathologic examination was
performed by the UCSF Liver Center Pathology, Histology and Light
Microscopy Cores.
Statistical Analyses. In a strict statistical sense, this study is
exploratory by nature and accordingly, all statistical analyses,
employing the Student’s t test, should be considered descriptive and
not hypothesis-testing. Our sample size was planned to be at least
three male mice, but final sample sizes depended on how many male
mice were in a given litter.
Results
Verification of the Liver-Conditional gp78-KO Mouse
Genotype
The cgt-targeting strategy employed is shown (Fig. 1A). This
strategy is different from that reported previously (Liu et al.,
2012) in that the cgt cassette targeted only seven to eight exons
(vs. five to eight), and it also employed resuscitated cryopre-
served embryos rather than genetically engineered embryonic
stem cells as the starting material. Verification of the genomic
DNA by tail-clip genotyping via PCR analyses of wild-type (WT;
gp781/1) flp/flp-mice, cgt/1, gp781/2, and gp782/2 mice, respec-
tively, is shown (Fig. 1, B andC). Parallel IB analyses of liver and
brain tissue lysates from WT and gp782/2-mice provided un-
equivocal evidence of liver-conditional gp78 KO (Fig. 1D).
Identification of Hepatic P450s as gp78 Targets
IB analyses of lysates from untreated, freshly isolated
hepatocytes revealed the statistically significant stabilization
of constitutive Cyp2e1 and Cyps 3a upon liver-conditional
gp78 KO relative to corresponding age/strain-matched WT
mice (Fig. 2). A slight, albeit statistically significant relative
stabilization of constitutive Cyps 2c was also likewise detected
(Fig. 2). By contrast, the expression of constitutive Cyps 2a, for
reasons currently unclear, was statistically significantly de-
creased upon gp78 KO (Fig. 2). Furthermore, consistent with
our gp78-shRNAi findings in cultured rat hepatocytes, IB
analyses of lysates from cultured mouse hepatocytes verified
that DEX-inducible Cyps 3a and INH-inducible Cyp2e1 were
also statistically significantly stabilized upon gp78 KO
(gp782/2) relative to those in the WT (Fig. 3). Corresponding
diagnostic functional probes revealed that this stabilization
was largely of the functionally active forms (Fig. 4). Similar
conclusions were also drawn for PB-inducible Cyps 2c (Figs. 3
and 4). TheCyp1a2 increase in gp782/2 hepatocytes relative to
the WT hepatocytes, on the other hand, may be partially
attributable to transcriptional induction (Fig. 5). By contrast,
the relative hepatic content and corresponding functional
activity of Cyps 2d were unaffected, whereas those of Cyps
2b were even decreased upon gp78 KO (Figs. 3 and 4).
Surprisingly, in contrast to the statistically significant re-
duction of constitutive Cyps 2a (Fig. 2), a marked stabilization
of PB-inducible Cyps 2a was observed in gp782/2 over gp781/1
hepatocytes (Fig. 3), with a correspondingly marked relative
increase of coumarin-7-hydroxylase in gp782/2 over gp781/1
hepatocytes (Fig. 4). Thus, in addition to Cyps 3a and Cyp2e1,
these studies identified Cyps 2a and Cyps 2c as gp78 targets,
with their diagnostic functional probes attesting to their
corresponding statistically significant functional increases.
Furthermore, on the basis of: 1) the observed PB inducibility of
the Cyp2a enzyme; 2) its close functional correlation with the
elevated coumarin-7-hydroxylase activity, an excellent Cyp2a5
but not Cyp2a4-diagnostic probe (Chang and Waxman, 1996),
coupled with 3) its ability for cotinine and trans-39-hydroxycoti-
nine formation (see below; Zhou et al., 2010), lead us to propose
Cyp2a5 as the Cyp2a isoform most probably stabilized.
Functional P450 Enhancement Results from Corre-
sponding P450 Protein Stabilization upon gp78 KO.
We have previously reported that the CYP3A stabilization
upon lentiviral shRNAi-elicited gp78 knockdown in cultured
rat hepatocytes is attributable to its protein stabilization
rather than increased CYP3A mRNA expression (Kim et al.,
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2010). Relative hepatic P450 mRNA expression analyses by
qRT-PCR analyses of total RNA isolated from gp782/2 and
gp781/1 hepatocytes after each P450-inducer pretreatment
coupled with the use of P450 isoform-specific probes revealed
that the observed relative P450 content and functional
increases (except in the case of Cyp1a2) were not caused by
their transcriptional mRNA induction (Fig. 5).
Cycloheximide-chase analyses of gp782/2 and gp781/1 he-
patocytes coupled with concurrent treatment with either the
proteasome inhibitor bortezomib or the ALD inhibitors (3-MA/
NH4Cl) revealed that Cyp2a5 degradation was considerably
slower in gp782/2 hepatocytes relative to gp781/1 hepatocytes
but involved both UPD and ALD (Fig. 6A). Cyp2a5 immuno-
precipitation from PB-pretreated gp782/2 and gp781/1 hepa-
tocytes and protein ubiquitination analyses directly verified
that Cyp2a5 was primarily a gp78 target, as its ubiquitinated
level was markedly reduced upon gp78 KO, and bortezomib-
mediated inhibition of its proteasomal degradation failed to
enhance it (Fig. 6B). Thus, gp78-mediated Cyp2a5 ubiquiti-
nation targets the protein for both UPD and ALD.
Pharmacological Relevance of Hepatic P450 Stabilization
upon gp78 KO
With the exception of coumarin, the above functional
analyses employed readily assayable fluorescent diagnostic
probes rather than therapeutic and/or pharmacologically
active drugs as substrates. To determine the potential ther-
apeutic relevance of CYP2e1 stabilization upon gp78 KO, we
examined in gp782/2 and gp781/1 hepatocytes the Cyp2e1-
dependent 6-hydroxylation of chlorzoxazone, a clinically pre-
scribed skeletal muscle relaxant and an established Cyp2e1
functional probe, (Fig. 7A). A statistically significant relative
increase was detected in 6-OH-chlorzoxazone formation in
gp782/2 over gp781/1 hepatocytes (Fig. 7A), comparable to
that observed with its other diagnostic Cyp2e1 probe (MFC)
(Fig. 4), thus underscoring the potential therapeutic signifi-
cance of these findings.
Cyp2e1 largely and Cyps 3a to a lesser extent are also
involved in the metabolism of the clinically prescribed non-
steroidal analgesic acetaminophen (APAP) to its reactive
nucleophilic species N-acetylparaquinoneimine (NAPQI)
(Lee et al., 1996; Wolf et al., 2007). This pathway becomes
increasingly hepatotoxigenic when liver concentrations of
ingested APAP exceed the detoxification capability of its
hepatic glucuronidation and sulfation pathways (Gillette
et al., 1981; Nelson, 1990). More of the parent drug is then
shunted into the reactive NAPQI pathway with consequent
liver damage that can be clinically fatal (Nelson, 1990). To
determine the potentially hepatotoxicological relevance of
Cyp2e1 functional stabilization upon gp78 KO, we examined
INH-pretreated gp782/2 and gp781/1 hepatocytes treated
with APAP at two different concentrations: 5 mM, the
concentration routinely employed to trigger APAP-induced
Fig. 2. IB analyses of constitutive hepatic P450s from
WT and gp78-KO mice. (A) IB analyses of a representa-
tive mouse sample. (B) Densitometric quantification of
the approx. 50–55 kDa P450 band from hepatocytes
freshly isolated and uncultured from three individual
WT and gp78-KO mice. See Materials and Methods for
details. Values (mean6 S.D.) of three individual experi-
ments, each employing two culture plates (technical
replicates) of hepatocytes isolated from each of the three
mice. Statistical significance determined by the Stu-
dent’s t test, *,***P, 0.05, and 0.001 vs.WT, respectively.
Fig. 3. IB analyses of hepatic P450s from cultured WT
and gp78-KO mouse hepatocytes. (A) IB analyses of
a representative mouse sample. (B) Densitometric
quantification of the approx. 50- to 55-kDa P450 band
from hepatocytes isolated from three individual WT and
gp78-KO mice, cultured and pretreated with P450-
inducers. SeeMaterials and Methods for details. Values
(mean 6 S.D.) of three individual experiments, each
employing two culture plates (technical replicates) of
hepatocytes isolated from each of the three mice.
Statistical significance determined by the Student’s
t test, *,**,***P, 0.05, 0.01, and 0.001 vs.WT, respectively.
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liver damage (Burcham and Harman, 1991; Bajt et al., 2004),
and 1 mM, one-fifth the toxic concentration, over 24 hours of
culture. Although, as expected, the 5-mM concentration led to
statistically significantly increased injury to gp781/1 hepato-
cytes, as monitored by the extracellular spillage into the cell
medium of the liver cytoplasm-specific ALT enzyme, this was
statistically significantly greater in gp782/2 hepatocytes
(Fig. 7B). At the 1-mM concentration, however, although
APAP produced a mild extracellular ALT rise in gp781/1
hepatocytes, this was considerably accelerated and pro-
nouncedly greater in gp782/2 hepatocytes (Fig. 7B). These
findings thus attest to the relevance of P450 stabilization upon
gp78 KO to drugs whose hepatotoxigenic potential largely
depends on their Cyp2e1-mediated bioactivation.
Furthermore, to determine the pharmacological relevance
of the relatively marked functional Cyp2a5-stabilization, we
also determined its effects on the metabolism of its prototype
drug substrate nicotine, a pharmacologically active drug
(Fig. 8). As expected, nicotine was metabolized to cotinine
(via the nicotine-iminium ion and subsequent oxidation by
aldehyde oxidase), nornicotine, norcotinine, trans-39-hydrox-
ycotinine, nicotine-N-oxide, and cotinine-N-oxide (Cashman
et al., 1992; Nakajima et al., 1996; Hukkanen et al., 2005; Siu
et al., 2006; Zhou et al., 2010). Whereas the nicotine-N-oxide is
reportedly generated by flavin-monooxygenase (FMO3;
Cashman et al., 1992), the other four metabolites are gener-
ated by various P450s, of which Cyp2a5 is the major catalyst
(Nakajima et al., 1996; Siu et al., 2006; Zhou et al., 2010). On
the other hand, trans-39-hydroxycotinine is selectively gener-
ated by CYP2A6, a Cyp2a5 ortholog (Nakajima et al., 1996;
Siu et al., 2006; Zhou et al., 2010). Our results revealed that,
indeed, from 2 hours onwards, consistent with the marked
increase in Cyp2a5, there is a statistically significant, accel-
erated increase in cotinine formation, with a 2-fold increase in
trans-39-hydroxycotinine formation detected at 24 hours in
gp782/2 over gp781/1 hepatocytes (Fig. 8)—thus, not quite as
high as the marked functional fold-increases observed with
the diagnostic Cyp2a5 functional marker (coumarin) (Fig. 4)
but statistically significant nonetheless. One issue with
monitoring secondary drug metabolism in isolated cultured
hepatocytes in general is that the primary metabolite (coti-
nine) spills out into the cell medium almost as quickly as it is
generated, thus not allowing sufficient time for its subsequent
Cyp2a5-selective trans-39-hydroxycotinine conversion. Thus,
only when sufficient cotinine accumulates intracellularly with
time (24 hours) is the trans-39-hydroxycotinine conversion
detectable (Fig. 8). This is also true of the other P450-
dependent cotinine metabolites, whose relative increases
were maximally detected at 24 hours. By contrast, the FMO3
metabolite nicotine-N-oxide was decreased, rather than
increased, in gp782/2 hepatocytes, thereby revealing that
FMO3 was, if at all, decreased rather than increased upon
gp78 KO. The other issue is that nicotine itself may incur
enhanced substrate competition by other P450s that not only
are known to metabolize it (Zhou et al., 2010) but are also
increased upon gp78 KO, which is not the case with the
Fig. 4. P450 functional screening using diagnostic fluorescent probes. Hepatocytes from three WT and gp78-KO mice were cultured separately,
pretreated with P450-inducers, and then incubated with individual diagnostic functional probes at time 0 hour. SeeMaterials and Methods for details.
Values (mean 6 S.D.) of three individual experiments each employing two culture plates (technical replicates) of hepatocytes isolated from each of the
three mice. Statistical significance determined by the Student’s t test, *,**,***P , 0.05, 0.01, and 0.001 vs. WT, respectively.
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relatively more selective Cyp2a5 diagnostic probe. Nevertheless,
these findings indicate that gp78 KO can statistically
significantly increase the metabolism of pharmacologically
active drugs by enhancing hepatic Cyp2a5 levels through
protein stabilization.
Pharmacologically relevant drugs often involve multiple
hepatic P450s, each catalyzing a different step of their
biotransformation pathway. Such biotransformation is rele-
vant not only to their elimination, DDIs, and toxicity but also
often to their pharmacological response through prodrug
metabolic bioactivation. We therefore sought to determine
the relevance of gp78 KO to the bioactivation of the estrogen
receptor–positive breast cancer therapeutic prodrug tamox-
ifen. Tamoxifen bioactivation involves two concurrent al-
ternate sequential metabolic routes (Fig. 9; Jacolot et al.,
1991; Desta et al., 2004; Goetz et al., 2007): It can be first
converted to 4-hydroxytamoxifen by Cyp2d, which is then
N-demethylated by Cyps 3a to generate endoxifen. Alter-
natively, it could be first N-demethylated by Cyps 3a to
N-desmethyltamoxifen, which is then 4-hydroxylated by
Cyp2d to generate endoxifen (Jacolot et al., 1991; Desta
et al., 2004). Both routes thus generate endoxifen, the
ultimately desired bioactive chemotherapeutic entity. Our
findings reveal that upon gp78 KO, although the Cyp2d-
dependent 4-hydroxylation step remains unchanged,
consistent with unaltered hepatic Cyp2d levels, the bio-
activation of tamoxifen to endotoxifen is nevertheless
statistically significantly increased consistent with func-
tional Cyp3a stabilization, and would be therapeutically
relevant (Fig. 9).
In Vivo Relevance of the P450 Stabilization
Toxicological Implications. Our findings in cultured
mouse hepatocytes upon genetic gp78 ablation, albeit pro-
viding proof of principle, may be equivocal and thus not
entirely convincing of their plausible in vivo import. To
specifically define their physiologic/toxicologic relevance
in vivo, we employed the in vivo correlate of our APAP-
treated cell culture model. Accordingly, male mice (8-week-
old) treated with a mildly toxic APAP (200 mg/kg, i.p.) dose at
time 0 documented progressively increased serum ALT levels
at 6 and 12 hours after treatment that were statistically
significantly higher in gp78-KO mice than those in corre-
spondingly treated WT mice (Fig. 10A). Concurrently, as in
Fig. 2, hepatic Cyp2e1 and Cyp3a content in these mice, not
treated with any P450 inducers, was statistically significantly
elevated in gp78-KO relative to WT mice 12 hours post-APAP
(Fig. 10, B and C). Correspondingly, the relative increases in
hepatic MDA-levels (Fig. 10C), a reflection of Cyp2e1/Cyp3a-
mediated enhanced APAP metabolism to the redox-active
NAPQI species and consequent ROS generation, were also
more pronounced in the gp78-KO than in WT mice. Although
the APAP (200 mg/kg) dose administered was mildly toxic,
characteristic APAP-elicited hepatic injury was observed in
all gp78-KO and WT mice at 12 hours postadministration
(Mitchell et al., 1973;McGill et al., 2013; Bhushan et al., 2014).
More importantly, the severity of the hepatic centrizonal gross
necrosis elicited by the mildly toxic APAP dose was consider-
ably greater in the gp78 KO than in the correspondingly
treated WT mice—with pyknotic nuclei, karyorrhexis, kar-
yolysis, and cytoplasmic eosinophilia of the necrotic hepato-
cytes bridging adjacent lobules; polymorphonuclear cell
infiltration; and the congestion of the hepatic sinusoidal
spaces in the centrilobular and midzonal regions. Further-
more, judging by the perimeter of the polymorphonuclear
cell infiltration “collar” of these coalesced necrotic lobules,
this APAP-elicited hepatic necrosis was much more exten-
sive in the gp78-KO than in the WT mice. Collectively, these
findings not only underscore the therapeutic/hepatotoxicological
relevance of hepatic Cyp2e1 and Cyp3a stabilization upon
gp78 KO but also validate similar findings in cultured
hepatocytes (Fig. 7B).
Discussion
We document herein for the first time that mouse hepatic
Cyp2a5 and Cyps 2c, in addition to previously established
Cyps 3a and Cyp2e1, are functionally stabilized upon liver-
conditional gp78/AMFR KO. Furthermore, we provide con-
crete novel evidence that Cyp2a5 not only is primarily
a ubiquitination target of gp78 E3-ligase, but also, despite
the preferential gp78 mode of K48-linked rather than K63-
linked ubiquitination (Li et al., 2007), Cyp2a5 is targeted to
both UPD and ALD. On the basis of our findings regarding
their human CYP2C9 ortholog, Cyps 2c are quite probably
also gp78-ubiquitination substrates (Kim et al., 2016b). Thus,
the observed hepatic P450 stabilization upon disruption of
their UPD through gp78 KO provides additional therapeuti-
cally relevant examples of eukaryotic protein induction via
protein stabilization (Schimke and Doyle, 1970).
The mouse hepatic P450s stabilized upon gp78 KO have
corresponding human orthologs that are involved not just in
Fig. 5. Relative P450 mRNA expression in cultured WT and gp78-KO
mouse hepatocytes. Total RNA was extracted on day 4 from cultured
hepatocytes, untreated or pretreated with P450 inducers for 3 days.
Hepatic P450 mRNA expression was determined by qRT-PCR analyses
as detailed in Materials and Methods. Values (mean 6 S.D.) are derived
from three individual cultures pretreated with P450 inducers as detailed.
Statistical significance determined by the Student’s t test, *P , 0.05 vs.
WT. GAPDH mRNA Ct levels (mean 6 S.D.) between P450-inducer
pretreated WT and gp78-KO cultured hepatocytes were as follows: bNF:
100 6 1.92 (WT)/101.49 6 1.75 (gp78 KO); PB: 100 6 1.67 (WT)/100.33 6
1.61 (gp78 KO); INH: 1006 1.99 (WT)/99.726 1.66 (gp78 KO); DEX: 1006
2.19 (WT)/102.856 3.94 (gp78 KO). No statistically significant differences
were noted by the Student’s t test in GAPDH Ct values between WT and
gp78-KO cultured hepatocytes pretreated with each of the four P450
inducers. Ct, threshold cycle.
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the metabolism and elimination of many clinically prescribed
drugs, dietary agents, and environmental xenobiotics but also
in their biotransformation either to more pharmacologically
active or even more toxic/carcinogenic/mutagenic species
(Guengerich, 2015; Correia, 2018). Employing pharmacologi-
cal agents with therapeutic and/or hepatotoxigenic potential,
we document herein that such hepatic P450 functional
stabilization, if occurring in humans likewise, would be of
clinical relevance. Accordingly, most therapeutic agents iden-
tified as specific substrates of a given hepatic P450 that is
functionally stabilized upon gp78 KO would experience en-
hanced clearance and accelerated termination of their phar-
macological action. Their therapeutic responses consequently
would be curtailed, much akin to the impaired drug responses
observed upon co-ingestion of therapeutic or dietary P450
inducers. For drugs such as nicotine, metabolized predomi-
nantly by human CYP2A6, its functional stabilization, while
accelerating nicotine clearance, may also lead to enhanced
nicotine craving in chronic cigarette smokers, and thus to an
altered behavioral response. Moreover, given the major
Fig. 6. Hepatic Cyp2a5 UPD and ALD: a major role of gp78 in Cyp2a5 ubiquitination. (A) Cycloheximide-chase analyses of hepatocytes from three
individual WT and gp78-KO mice were cultured, PB-pretreated for 3 days, and on day 4 treated with or without the proteasomal inhibitor bortezomib
(BTZ) or the ALD-inhibitors 3-MA/NH4Cl for 0, 8, and 24 hours before cell harvesting. Cell lysates were immunoblotted for Cyp2a or gp78 with actin as
a loading control. Densitometric quantification (mean6 S.D.) of individual cultures from three mice. Statistical significance determined by the Student’s
t test, ***P, 0.001 vs. WT at 0 hour; ##, ###P, 0.01, 0.001 vs. WT1 CHX; xP, 0.05 vs. KO at 0 hour. (B) Representative Ub-immunoblotting analyses of
Cyp2a-immunoprecipitates from aliquots of PB-pretreated cultured cell lysates obtained from two of the three different mice treated with or without BTZ
as in (A).
Fig. 7. Relative chlorzoxazone metabolism and APAP-elicited liver injury in cultured WT and gp78-KO mouse hepatocytes. (A) INH-pretreated
hepatocytes (three individual cultures) fromWT and gp78-KOmice were incubated on day 4 with chlorzoxazone for 3 hours and 6-hydroxychlorzoxazone
assayed as detailed in Materials and Methods. Values (mean 6 S.D.) of three individual cultures. Statistical significance determined by the Student’s
t test, *P, 0.05 vs. WT. (B) WT and gp78-KO mouse hepatocyte cultures were INH-pretreated, and on day 4 incubated with APAP (1 or 5 mM) for 0–24
hours. Aliquots ofmedia were taken at the time points indicated and assayed for ALT activity as detailed inMaterials andMethods. Values (mean6 S.D.)
of three individual cultures. Statistical significance determined by the Student’s t test, *P , 0.05 vs. WT, **P , 0.01 vs. WT.
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CYP2A6 role in the bioactivation of tobacco nitrosamines,
including the tobacco-specific lung carcinogen 4-(methylnitro-
samino)-1-(3-pyridyl)-1-butanone (NNK) and other toxic
nitrosamines (Zhou et al., 2012; Zhu et al., 2013; Yuan et al.,
2017), their carcinogenicity would also be enhanced.
Importantly, because many of these P450s are also involved
in the metabolism of drugs (i.e., cancer chemotherapeutic
agents) with narrow therapeutic indices, even minor oscilla-
tions in hepatic P450 content may translate into therapeuti-
cally undesirable losses of their pharmacological efficacy on
the one hand, and toxicity on the other, as underscored
previously (Peer et al., 2011) in support of the clinical
relevance of our CHIP and gp78-shRNAi findings (Kim
et al., 2010). Additionally, such enhanced hepatic P450 protein
stability can also augment drug-elicited toxicity. Thus, the
functional stabilization of hepatic Cyp2e1, and to a lesser
extent that of Cyp3a, rendered the mildly toxic concentrations
of APAP, a popular over-the-counter analgesic and a Cyp2e1/
Cyp3a substrate, statistically significantly more hepatotoxic
to gp782/2 hepatocytes than to corresponding WT both in
culture (Fig. 8) and live mice (Fig. 10). Although Cyp3a levels
are low without concurrent Cyp3a induction in cultured INH-
pretreated gp782/2 hepatocytes, gp78 ablation would sub-
stantially synergize such toxicity in vivo owing to the
Fig. 8. Relative nicotine metabolism in cultured WT and gp78-KO mouse hepatocytes. PB-pretreated hepatocytes from WT and gp78-KO mice were
cultured, and on day 4 incubated with nicotine for 0–24 hours. Aliquots of media were taken at the time points indicated and assayed as detailed in
Materials andMethods. The insert in the cotinine production graph is a magnified view of the initial three time points demarcated by the blue square. 3-
HC levels and 3-HC/cotinine ratios were determined at 24 hour. Values (mean6 S.D.) of three individual cultures. Statistical significance determined by
the Student’s t test, *P , 0.05 vs. WT, **P , 0.01 vs. WT, ***P , 0.001 vs. WT.
Fig. 9. Relative tamoxifen metabolism in cultured WT and gp78-KO mouse hepatocytes. WT and gp78-KO mouse hepatocyte cultures were DEX-
pretreated and on day 4 incubated with tamoxifen (40 mM) for 0–8 hours. Aliquots of cell media were taken at the time points indicated and assayed as
detailed inMaterials andMethods. Values (mean6 S.D.) of three individual cultures. Statistical significance determined by Student’s t test, *P, 0.05 or
**P , 0.01 vs. WT.
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functional stabilization of both hepatic Cyp2e1 and Cyps 3a
(Figs. 4 and 10).
However, such a functional P450 protein stabilization can
also be beneficial. Thus, our finding of the enhanced bioacti-
vation of the breast cancer chemotherapeutic prodrug tamox-
ifen in gp782/2 relative to WT hepatocytes is particularly
relevant and noteworthy. The E3 Ub-ligase gp78/AMFR was
originally identified as the cell surface receptor for the
prometastatic factor autocrine motility factor (Nabi et al.,
1990). Later, it was found to function as the E3 Ub-ligase in
the ERAD of several substrates, including the tumor meta-
static suppressor KAI1 (Fang et al., 2001; Tsai et al., 2007;
Chen et al., 2012). Indeed, gp78 levels are highly upregulated
within various human tumors (including lung, breast, and
colon) and their microenvironments, but not in adjacent
normal tissue (Chiu et al., 2008; Fairbank et al., 2009).
Importantly, this gp78 upregulation correlates with their
invasiveness, the severity of their metastatic progression,
and poor prognosis (Chiu et al., 2008; Fairbank et al., 2009).
Thus, African-American breast cancer patients, despite their
lower breast cancer incidence, exhibit markedly aggressive
breast cancer forms and higher mortality rates than their
European-American counterparts with lower mortality rates,
albeit much higher breast cancer incidence (Chiu et al., 2008;
Martin et al., 2009). Gene profiling via mRNA expression
analyses revealed that gp78/AMFR is one of the two genes
differentially elevated in the breast tumor epithelia and/or
stroma of African-American patients versus those of their
European-American cohorts. IB analyses documented a corre-
spondingly increased gp78 protein content in these tissues
(Martin et al., 2009). Likewise, a transgenic mouse mammary
glandgp78-overexpressionmodel also exhibited ahyperplastic
phenotype, increased ductal branching, and dense alveolar
lobule formation that correlated with its downregulation of
the KAI1 metastatic suppressor (Joshi et al., 2010). Thus,
given our findings of enhanced Cyp3a-mediated tamoxifen
bioactivation upon gp78 KO (Fig. 9), pharmacological attenua-
tion of gp78 function may be therapeutically desirable as an
adjuvant to concurrent breast cancer chemotherapy with pro-
drugs (such as tamoxifen) that are bioactivated by P450s.
Plausible adjuvants include aspirin, salicylates, and APAP that
activate p38 MAPK-elicited gp78-degradation, resulting in
CYP3A23 stabilization (Ohtsuki et al., 2019). However, although
such a short-term therapeutic gp78-inhibition strategy warrants
consideration, any long-term strategy may be contraindicated
given that aged gp78-null mice reportedly develop NASH and
human hepatocarcinoma (HHC) (Zhang et al., 2015a).
Over 600 known mammalian E3 Ub-ligases exist that are
functionally redundant in substrate recognition and targeting
(Metzger et al., 2014), and capable of serving in bothE3 andE4
(poly-Ub chain elongation of existing mono-ubiquitinated
residues) complementary roles (Morito et al., 2008; Wang
et al., 2014; Zhang et al., 2015b; Menzies et al., 2018).
Remarkably, despite these well recognized E3 features, the
genetic ablation of just a single hepatic E3, gp78/AMFR, is
sufficient to stabilize its target substrates, i.e., P450s, with
relevant pharmacological/toxic consequences.
Indeed, we recently documented that upon genetic CHIP
ablation in mice, hepatic Cyp2e1 was functionally stabilized
irrespective of the presence of gp78 and possibly other re-
dundant/complementary E3 Ub-ligases. This underscored the
principal role of UbcH5a/CHIP/Hsp70 as the relevant E3
complex in Cyp2e1 proteolytic turnover (Kim et al., 2016a).
This functional Cyp2e1 stabilization in vivo led to progres-
sively increased hepatic lipid peroxidation and oxidative
stress, JNK activation, and initial hepatic microvesicular
steatosis that upon aging developed into macrovesicular
steatosis, ushering a full-blown NASH syndrome over a 1-
year period (Kim et al., 2016a). These findings revealed that
abrogation of CHIP-mediated Cyp2e1 ubiquitination not only
has acute therapeutic/pharmacological consequences but also
severe, long-term pathophysiologic sequelae in mice.
Fig. 10. In vivo APAP-elicited liver injury in WT and gp78-KO mice. After an overnight fast (12 hours), mice (N 5 5 in each group) were treated with
APAP and their serum ALT levels determined at 0, 6, and 12 hours (A) as detailed (Materials and Methods). Mice were killed at 12 hours and their livers
used for Cyp2e1 andCyp3a IB analyses (B) and hepaticMDA levels (C) as described (Materials andMethods). The five individual values used for theMDA
(mean6S.D.) values are included in the bar graph. Statistical significance determined by the Student’s t test, *P, 0.05 or **P, 0.01 vs.WT. Liver injury
upon hematoxylin and eosin staining and microscopic histologic analyses of representative control and APAP-treated WT and gp78-KO mouse livers
isolated at 12 hours is shown in the right panels (D). ***P , 0.001 vs. WT.
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Surprisingly, comparable Cyp2e1-functional stabilization
upon liver-conditional gp78 KO, although toxicologically
relevant, did not result in a similar hepatic microvesicular
steatosis (D. Kwon and M. A. Correia, preliminary findings).
In fact, fructose-induced hepatic triglyceride (TG) and free
fatty acid content was statistically significantly lower in
gp782/2 relative to gp781/1 hepatocytes. This may stem from
two plausible synergistic scenarios: 1) Concurrent stabiliza-
tion of hepatic Insigs 1 and 2 upon gp78 KO suppresses SREB-
elicited hepatic lipid biosynthesis as reported in a similar
liver-conditional gp78-KO mouse model fed an obesity-
inducing diet (Liu et al., 2012); and/or 2) the concurrent
stabilization upon gp78 KO of apolipoprotein B100, an
established gp78 substrate (Liang et al., 2003) critically
involved in hepatic VLDL/LDL-packaging and export, accel-
erates extrahepatic TG export, thereby minimizing the poten-
tial for hepatic steatosis. Our observations and those of others
(Liu et al., 2012) reveal that upon their liver-conditional gp78
deletion, the mice are leaner and healthier, whereas global
genetic gp78 deletion enhances their risk of hepatic steatosis,
NASH, and HCC (Zhang et al., 2015a).
Although the gp78/AMFR upregulation in cancerous tissues
is widely documented and unequivocal (Chiu et al., 2008;
Martin et al., 2009), less clear is whether genetic gp78
polymorphisms normally exist in the general population,
engendering correspondingly high and low (defective) gp78
functional phenotypes. The PubMed online human AMFR
Gene/dbSNP Variant/Clin Variant databases list various
gp78/AMFR allelic variants, and classify some as benign and
others as pathologic. Arg/Arg mutations to Arg/Gly or Gly/Gly
at “locus 125/145” are claimed to correlate with a higher
expression of gp78 mRNA/protein, and correspondingly in-
creased incidence of coronary atherosclerotic disease in a Chi-
nese population (Wang et al., 2018b). The authors indicate
that the Arg/Arg residues at “locus” 145 or 125 were affected
by the polymorphism. However, the corresponding residues in
the human gp78/AMFR primary sequence deposited in
PubMed are Val145 and Phe125. The higher incidence of
neuroglioblastoma multiformis in an Iranian population has
also been associated with an AMFR genetic polymorphism
(Eishi Oskouei et al., 2018). The validity of these claims
remains however to be verifiedmore extensively. Although the
gp78 SNPs listed in the PubMed Database are present along
its entire 643 amino acid length, intriguingly, a few pertaining
to basic (K, R) residues in the functional gp78 cytoplasmic
domain target the very same positively charged residues that
we documented through chemical crosslinking/proteomic
analyses and site-directed mutagenesis to be involved in its
molecular recognition of CYP3A4 and CYP2E1 acidic phos-
phodegrons (Wang et al., 2015). Whether any of these listed
SNPs truly contribute to genetic gp78-polymorphisms in
human populations, and/or correspondingly alter hepatic
P450 content and function that trigger DDIs, remains to be
elucidated.
In summary, our findings document that the liver-specific
genetic ablation of the E3 Ub-ligase gp78/AMFR can result
through ERAD disruption in concurrent stabilization of
several therapeutically relevant P450s with potentially seri-
ous, unwarranted therapeutic and/or toxic consequences.
Such outcomes could be further aggravated in patients re-
quiring multiple drug therapies for their specific conditions.
Whereas for most drugs, accelerated elimination and
consequently shortened pharmacological response upon such
P450-stabilization may be largely undesirable, this feature
could also be ingeniously exploited as a therapeutic strategy in
certain instances to enhance the metabolic activation of
chemotherapeutic prodrugs with low therapeutic indices.
Acknowledgments
We thankChrisHer for liver cell isolation at theUCSFLiver Center
Core on Cell & Tissue Biology, and Kevin Siao for histological
assistance at the UCSF Liver Center Pathology Core supported by
NIDDK Center Grant DK26743. We thank Dr. Alexandra Ioanoviciu
for the training in the use of LC-MS system used in the tamoxifen
metabolite analyses. We greatly appreciate the contributions of Lisa
Yu and Trisha Mao for LC-MS/MS analyses of nicotine metabolites in
cell-culture samples, and funding from NIDA P30 DA012393 (to N.
Benowitz, UCSF) for supporting the laboratory resources used for
these analyses.
Authorship Contributions
Participated in research design: Kwon, Kim, Jacob, Correia.
Conducted experiments: Kwon, Kim, Liu.
Contributed new reagents or analytic tools: Kim, Jacob.
Performed data analysis: Kwon, Kim, Jacob.
Wrote or contributed to the writing of the manuscript: Kwon, Jacob,
Liu, Correia.
References
Acharya P, Liao M, Engel JC, and Correia MA (2011) Liver cytochrome P450 3A
endoplasmic reticulum-associated degradation: a major role for the p97 AAA
ATPase in cytochrome P450 3A extraction into the cytosol. J Biol Chem 286:
3815–3828.
Bajt ML, Knight TR, Lemasters JJ, and Jaeschke H (2004) Acetaminophen-induced
oxidant stress and cell injury in cultured mouse hepatocytes: protection by N-acetyl
cysteine. Toxicol Sci 80:343–349.
Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, and Patterson C (1999)
Identification of CHIP, a novel tetratricopeptide repeat-containing protein that
interacts with heat shock proteins and negatively regulates chaperone functions.
Mol Cell Biol 19:4535–4545.
Benowitz NL, Dains KM, Dempsey D, Yu L, and Jacob P III (2010) Estimation of
nicotine dose after low-level exposure using plasma and urine nicotine metabolites.
Cancer Epidemiol Biomarkers Prev 19:1160–1166.
Bhushan B, Walesky C, Manley M, Gallagher T, Borude P, Edwards G, Monga SP,
and Apte U (2014) Pro-regenerative signaling after acetaminophen-induced acute
liver injury in mice identified using a novel incremental dose model. Am J Pathol
184:3013–3025.
Binkhorst L, Mathijssen RH, Ghobadi Moghaddam-Helmantel IM, de Bruijn P, van
Gelder T, Wiemer EA, and Loos WJ (2011) Quantification of tamoxifen and three of
its phase-I metabolites in human plasma by liquid chromatography/triple-quad-
rupole mass spectrometry. J Pharm Biomed Anal 56:1016–1023.
Bradley A, Anastassiadis K, Ayadi A, Battey JF, Bell C, Birling MC, Bottomley J,
Brown SD, Bürger A, Bult CJ, et al. (2012) The mammalian gene function resource:
the International Knockout Mouse Consortium. Mamm Genome 23:580–586.
Burcham PC and Harman AW (1991) Acetaminophen toxicity results in site-specific
mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 266:5049–5054.
Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P III, and Benowitz NL (1992)
Metabolism of nicotine by human liver microsomes: stereoselective formation of
trans-nicotine N9-oxide. Chem Res Toxicol 5:639–646.
Chang TKH and Waxman DJ (1996) The CYP2A subfamily, in Cytochromes P450:
Metabolic and Toxicological Aspects (Ionnides C ed) pp 99–134, CRC Press, Boca
Raton, FL.
Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, and Weissman AM (2006) The
activity of a human endoplasmic reticulum-associated degradation E3, gp78,
requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci
USA 103:341–346.
Chen Z, Du S, and Fang S (2012) gp78: a multifaceted ubiquitin ligase that integrates
a unique protein degradation pathway from the endoplasmic reticulum. Curr
Protein Pept Sci 13:414–424.
Chiu CG, St-Pierre P, Nabi IR, and Wiseman SM (2008) Autocrine motility factor
receptor: a clinical review. Expert Rev Anticancer Ther 8:207–217.
Christianson JC and Ye Y (2014) Cleaning up in the endoplasmic reticulum: ubiq-
uitin in charge. Nat Struct Mol Biol 21:325–335.
Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Höhfeld J, and Patterson C
(2001) The co-chaperone CHIP regulates protein triage decisions mediated by heat-
shock proteins. Nat Cell Biol 3:93–96.
Correia MA (2018) Drug biotransformation, in Basic and Clinical Pharmacology
(Katzung BG ed) pp 56–73, McGraw Hill & Lange.
Correia MA, Davoll SH, Wrighton SA, and Thomas PE (1992) Degradation of rat liver
cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-
ethyl-1,4-dihydropyridine: characterization of the proteolytic system. Arch Bio-
chem Biophys 297:228–238.
652 Kwon et al.
 at A
SPET Journals on February 18, 2020
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Dahmane E, Mercier T, Zanolari B, Cruchon S, Guignard N, Buclin T, Leyvraz S,
Zaman K, Csajka C, and Decosterd LA (2010) An ultra performance liquid
chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma:
first evidence of 49-hydroxylated metabolites in breast cancer patients.
J Chromatogr B Analyt Technol Biomed Life Sci 878:3402–3414.
Desta Z, Ward BA, Soukhova NV, and Flockhart DA (2004) Comprehensive evalua-
tion of tamoxifen sequential biotransformation by the human cytochrome P450
system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther
310:1062–1075.
Donato MT, Jiménez N, Castell JV, and Gómez-Lechón MJ (2004) Fluorescence-
based assays for screening nine cytochrome P450 (P450) activities in intact cells
expressing individual human P450 enzymes. Drug Metab Dispos 32:699–706.
Eishi Oskouei A, Rafiee L, Mahzouni P, Gharipour M, and Javanmard SH (2018)
Association between autocrine motility factor receptor gene polymorphism
(rs2440472, rs373191257) and glioblastoma multiform in a representative Iranian
population. J Res Med Sci 23:96.
Eliasson E, Mkrtchian S, Halpert JR, and Ingelman-Sundberg M (1994) Substrate-
regulated, cAMP-dependent phosphorylation, denaturation, and degradation of
glucocorticoid-inducible rat liver cytochrome P450 3A1. J Biol Chem 269:
18378–18383.
Eliasson E, Mkrtchian S, and Ingelman-Sundberg M (1992) Hormone- and substrate-
regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-
activated rapid proteolysis in the endoplasmic reticulum membranes. J Biol Chem
267:15765–15769.
Fairbank M, St-Pierre P, and Nabi IR (2009) The complex biology of autocrine mo-
tility factor/phosphoglucose isomerase (AMF/PGI) and its receptor, the gp78/AMFR
E3 ubiquitin ligase. Mol Biosyst 5:793–801.
Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, and Weissman AM (2001) The
tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase im-
plicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci USA
98:14422–14427.
Faouzi S, Medzihradszky KF, Hefner C, Maher JJ, and Correia MA (2007) Charac-
terization of the physiological turnover of native and inactivated cytochromes P450
3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97? Bio-
chemistry 46:7793–7803.
Gillette JR, Nelson SD, Mulder GJ, Jollow DJ, Mitchell JR, Pohl LR, and Hinson JA
(1981) Formation of chemically reactive metabolites of phenacetin and acetamin-
ophen. Adv Exp Med Biol 136 (Pt B):931–950.
Girre C, Lucas D, Hispard E, Menez C, Dally S, and Menez JF (1994) Assessment of
cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmaco-
kinetics. Biochem Pharmacol 47:1503–1508.
Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW,
Reynolds C, Couch FJ, Lingle WL, et al. (2007) The impact of cytochrome P450 2D6
metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:
113–121.
Guengerich FP (2015) Human cytochrome P450 enzymes, in Cytochrome P450:
Structure, Mechanism and Biochemistry (Ortiz de Montellano P ed) pp 523–785,
Springer International publishing, New York.
Han XM, Lee G, Hefner C, Maher JJ, and Correia MA (2005) Heme-reversible im-
pairment of CYP2B1/2 induction in heme-depleted rat hepatocytes in primary
culture: translational control by a hepatic alpha-subunit of the eukaryotic initia-
tion factor kinase? J Pharmacol Exp Ther 314:128–138.
Hukkanen J, Jacob P III, and Benowitz NL (2005) Metabolism and disposition ki-
netics of nicotine. Pharmacol Rev 57:79–115.
Jacob P III, Yu L, Duan M, Ramos L, Yturralde O, and Benowitz NL (2011) De-
termination of the nicotine metabolites cotinine and trans-39-hydroxycotinine in
biologic fluids of smokers and non-smokers using liquid chromatography-tandem
mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping
cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci
879:267–276.
Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, and Berthou F (1991) Identification of
the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of
tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911–1919.
Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Höhfeld J, and Patterson C (2001)
CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target
for ubiquitylation. J Biol Chem 276:42938–42944.
Joshi B, Li L, and Nabi IR (2010) A role for KAI1 in promotion of cell proliferation
and mammary gland hyperplasia by the gp78 ubiquitin ligase. J Biol Chem 285:
8830–8839.
Joshi V, Upadhyay A, Kumar A, and Mishra A (2017) Gp78 E3 ubiquitin ligase:
essential functions and contributions in proteostasis. Front Cell Neurosci 11:259.
Kim SM, Acharya P, Engel JC, and Correia MA (2010) Liver cytochrome P450 3A
ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of
Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and phar-
macological relevance. J Biol Chem 285:35866–35877.
Kim SM, Grenert JP, Patterson C, and Correia MA (2016a) CHIP(-/-)-mouse liver:
adiponectin-AMPK-FOXO-activation overrides CYP2e1-elicited JNK1-activation,
delaying onset of NASH: therapeutic implications. Sci Rep 6:29423.
Kim SM, Wang Y, Nabavi N, Liu Y, and Correia MA (2016b) Hepatic cytochromes
P450: structural degrons and barcodes, posttranslational modifications and cellu-
lar adapters in the ERAD-endgame. Drug Metab Rev 48:405–433.
Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, and Gonzalez FJ (1996) Role of
CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063–12067.
Li W, Tu D, Brunger AT, and Ye Y (2007) A ubiquitin ligase transfers preformed
polyubiquitin chains from a conjugating enzyme to a substrate. Nature 446:
333–337.
Liang JS, Kim T, Fang S, Yamaguchi J, Weissman AM, Fisher EA, and Ginsberg HN
(2003) Overexpression of the tumor autocrine motility factor receptor Gp78,
a ubiquitin protein ligase, results in increased ubiquitinylation and decreased se-
cretion of apolipoprotein B100 in HepG2 cells. J Biol Chem 278:23984–23988.
Liao M, Faouzi S, Karyakin A, and Correia MA (2006) Endoplasmic reticulum-
associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae:
further characterization of cellular participants and structural determinants. Mol
Pharmacol 69:1897–1904.
Liu TF, Tang JJ, Li PS, Shen Y, Li JG, Miao HH, Li BL, and Song BL (2012) Ablation
of gp78 in liver improves hyperlipidemia and insulin resistance by inhibiting
SREBP to decrease lipid biosynthesis. Cell Metab 16:213–225.
Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, Tsai YC, Williams
EH, Lee DH, Stephens RM, et al. (2009) Differences in the tumor microenviron-
ment between African-American and European-American breast cancer patients.
PLoS One 4:e4531.
McGill MR, Lebofsky M, Norris HR, Slawson MH, Bajt ML, Xie Y, Williams CD,
Wilkins DG, Rollins DE, and Jaeschke H (2013) Plasma and liver acetaminophen-
protein adduct levels in mice after acetaminophen treatment: dose-response,
mechanisms, and clinical implications. Toxicol Appl Pharmacol 269:240–249.
Menzies SA, Volkmar N, van den Boomen DJ, Timms RT, Dickson AS, Nathan JA,
and Lehner PJ (2018) The sterol-responsive RNF145 E3 ubiquitin ligase mediates
the degradation of HMG-CoA reductase together with gp78 and Hrd1. eLife 7:
e40009, doi: 10.7554/eLife.40009.
Metzger MB, Pruneda JN, Klevit RE, and Weissman AM (2014) RING-type E3
ligases: master manipulators of E2 ubiquitin-conjugating enzymes and ubiquiti-
nation. Biochim Biophys Acta 1843:47–60.
Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, and Brodie BB (1973)
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol
Exp Ther 187:185–194.
Morishima Y, Peng HM, Lin HL, Hollenberg PF, Sunahara RK, Osawa Y, and Pratt
WB (2005) Regulation of cytochrome P450 2E1 by heat shock protein 90-dependent
stabilization and CHIP-dependent proteasomal degradation. Biochemistry 44:
16333–16340.
Morito D, Hirao K, Oda Y, Hosokawa N, Tokunaga F, Cyr DM, Tanaka K, Iwai K,
and Nagata K (2008) Gp78 cooperates with RMA1 in endoplasmic reticulum-
associated degradation of CFTRDeltaF508. Mol Biol Cell 19:1328–1336.
Murata S, Minami Y, Minami M, Chiba T, and Tanaka K (2001) CHIP is a chaperone-
dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2:1133–1138.
Nabi IR, Watanabe H, and Raz A (1990) Identification of B16-F1 melanoma autocrine
motility-like factor receptor. Cancer Res 50:409–414.
Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y,
Shimada N, Kamataki T, and Kuroiwa Y (1996) Role of human cytochrome
P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212–1217.
Needham PG, Guerriero CJ, and Brodsky JL (2019) Chaperoning endoplasmic
reticulum-associated degradation (ERAD) and protein conformational diseases.
Cold Spring Harb Perspect Biol 11:a033928, doi: 10.1101/cshperspect.a033928.
Nelson SD (1990) Molecular mechanisms of the hepatotoxicity caused by acetamin-
ophen. Semin Liver Dis 10:267–278.
Ohtsuki Y, Sanoh S, Santoh M, Ejiri Y, Ohta S, and Kotake Y (2019) Inhibition of
cytochrome P450 3A protein degradation and subsequent increase in enzymatic
activity through p38 MAPK activation by acetaminophen and salicylate deriva-
tives. Biochem Biophys Res Commun 509:287–293.
Olzmann JA, Kopito RR, and Christianson JC (2013) The mammalian endoplasmic
reticulum-associated degradation system. Cold Spring Harb Perspect Biol 5:
a013185.
Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, and Correia MA (2009)
CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor,
AMFR) and CHIP E3 ligases. Arch Biochem Biophys 483:66–74.
Peer CJ, Sissung TM, and Figg WD (2011) CHIP and gp78-mediated ubiquitination
of CYP3A4: implications for the pharmacology of anticancer agents. Cancer Biol
Ther 11:549–551.
Postic C and Magnuson MA (2000) DNA excision in liver by an albumin-Cre trans-
gene occurs progressively with age. Genesis 26:149–150.
Preston GM and Brodsky JL (2017) The evolving role of ubiquitin modification in
endoplasmic reticulum-associated degradation. Biochem J 474:445–469.
Schimke RT and Doyle D (1970) Control of enzyme levels in animal tissues. Annu Rev
Biochem 39:929–976.
Siu EC, Wildenauer DB, and Tyndale RF (2006) Nicotine self-administration in mice
is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology
(Berl) 184:401–408.
Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO,
Thomas M, Harrow J, Cox T, et al. (2011) A conditional knockout resource for the
genome-wide study of mouse gene function. Nature 474:337–342.
Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt
SM, Helman LJ, Khanna C, et al. (2007) The ubiquitin ligase gp78 promotes sar-
coma metastasis by targeting KAI1 for degradation. Nat Med 13:1504–1509.
Wang HF, Figueiredo Pereira ME, and Correia MA (1999) Cytochrome P450 3A
degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch
Biochem Biophys 365:45–53.
Wang L, Bernert JT, Benowitz NL, Feng J, Jacob P III, McGahee E, Caudill SP,
Scherer G, Scherer M, Pluym N, et al. (2018a) Collaborative method perfor-
mance study of the measurement of nicotine, its metabolites, and total nicotine
equivalents in human urine. Cancer Epidemiol Biomarkers Prev 27:
1083–1090.
Wang L, Li HC, Zhou J, Yang B, Qiao CD, Liu YM, and Zhang Z (2018b) Correlation
between the GP78 gene polymorphism and coronary atherosclerotic heart disease.
Hellenic J Cardiol 59:8–13.
Wang X, Medzihradszky KF, Maltby D, and Correia MA (2001) Phosphorylation of
native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric
characterization of the phosphorylated peptides. Biochemistry 40:11318–11326.
Wang Y, Guan S, Acharya P, Koop DR, Liu Y, Liao M, Burlingame AL, and Correia
MA (2011) Ubiquitin-dependent proteasomal degradation of human liver cyto-
chrome P450 2E1: identification of sites targeted for phosphorylation and ubiq-
uitination. J Biol Chem 286:9443–9456.
gp78/AMFR E3-Knockout Enhances Hepatic P450 Function 653
 at A
SPET Journals on February 18, 2020
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
Wang Y, Guan S, Acharya P, Liu Y, Thirumaran RK, Brandman R, Schuetz EG, Burlin-
game AL, and Correia MA (2012) Multisite phosphorylation of human liver cytochrome
P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-
478 residue in the gp78-catalyzed reaction. Mol Cell Proteomics 11:M111.010132.
Wang Y, Ha SW, Zhang T, Kho DH, Raz A, and Xie Y (2014) Polyubiquitylation of
AMF requires cooperation between the gp78 and TRIM25 ubiquitin ligases.
Oncotarget 5:2044–2051.
Wang Y, Kim SM, Trnka MJ, Liu Y, Burlingame AL, and Correia MA (2015) Human
liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78
autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiq-
uitin ligase complexes. J Biol Chem 290:3308–3332.
Wang Y, Liao M, Hoe N, Acharya P, Deng C, Krutchinsky AN, and Correia MA (2009)
A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent
proteasomal degradation. J Biol Chem 284:5671–5684.
Wolf KK, Wood SG, Allard JL, Hunt JA, Gorman N, Walton-Strong BW, Szakacs JG,
Duan SX, Hao Q, Court MH, et al. (2007) Role of CYP3A and CYP2E1 in alcohol-
mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and
Cyp2e1(-/-) mice. Drug Metab Dispos 35:1223–1231.
Yuan JM, Nelson HH, Carmella SG, Wang R, Kuriger-Laber J, Jin A, Adams-Haduch
J, Hecht SS, Koh WP, and Murphy SE (2017) CYP2A6 genetic polymorphisms and
biomarkers of tobacco smoke constituents in relation to risk of lung cancer in the
Singapore Chinese Health Study. Carcinogenesis 38:411–418.
Zhang T, Kho DH, Wang Y, Harazono Y, Nakajima K, Xie Y, and Raz A (2015a) Gp78,
an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepa-
titis (NASH) and liver cancer. PLoS One 10:e0118448.
Zhang T, Xu Y, Liu Y, and Ye Y (2015b) gp78 functions downstream of Hrd1 to
promote degradation of misfolded proteins of the endoplasmic reticulum. Mol Biol
Cell 26:4438–4450.
Zhong X, Shen Y, Ballar P, Apostolou A, Agami R, and Fang S (2004) AAA
ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase
for endoplasmic reticulum-associated degradation. J Biol Chem 279:
45676–45684.
Zhou X, D’Agostino J, Xie F, and Ding X (2012) Role of CYP2A5 in the bioactivation of
the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice.
J Pharmacol Exp Ther 341:233–241.
Zhou X, Zhuo X, Xie F, Kluetzman K, Shu YZ, Humphreys WG, and Ding X (2010)
Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on
a Cyp2a5-null mouse model. J Pharmacol Exp Ther 332:578–587.
Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, Watson
CH, Sosnoff CS, Benowitz NL, and Tyndale RF (2013) Alaska native smokers and
smokeless tobacco users with slower CYP2A6 activity have lower tobacco con-
sumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific
nitrosamine bioactivation. Carcinogenesis 34:93–101.
Address correspondence to: Dr. Maria Almira Correia, Cellular &
Molecular Pharmacology, University of California San Francisco, Genentech
Hall, 600 16th Street, Box 2280, San Francisco, CA 94158-2517. E-mail:
almira.correia@ucsf.edu
654 Kwon et al.
 at A
SPET Journals on February 18, 2020
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
